HS-20117 + HS-20093 + 5-fluorouracil

HS-20117 + HS-20093 + 5-fluorouracil is an experimental combination regimen being investigated in advanced solid tumors. HS-20117 is a fully human immunoglobulin G1 (IgG1)-like bispecific antibody targeting EGFR and MET, designed to inhibit two oncogenic pathways simultaneously. HS-20093 is a B7-H3-targeted antibody-drug conjugate (ADC), consisting of a fully humanized anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload; the B7-H3 target is highly expressed on multiple solid tumors, and the ADC delivers cytotoxic payload directly to cancer cells. 5-fluorouracil is a cytotoxic pyrimidine analog chemotherapeutic agent that inhibits thymidylate synthase, interfering with DNA synthesis and repair. The combination aims to leverage targeted immunotherapy (dual receptor and B7-H3 targeting) with systemic cytotoxic chemotherapy for improved antitumor efficacy. The regimen is in Phase I investigation for advanced solid tumors and certain malignancies such as non-small cell lung cancer, colorectal cancer, and other solid cancers[1][3][5].

Other names

5-FU